Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.[1]
It is a humanized monoclonal antibody that binds to
hepatocyte growth factor, thus inhibiting the
c-MET receptor signaling cascade.[2]
Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing
gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with
non-small cell lung cancer.[3]
^Panahi Y, Mohammadzadeh AH, Behnam B, Orafai HM, Jamialahmadi T, Sahebkar A (2021). "A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer". Reviews on New Drug Targets in Age-Related Disorders. Advances in Experimental Medicine and Biology. Vol. 1286. pp. 49–64 (57).
doi:
10.1007/978-3-030-55035-6_3.
ISBN978-3-030-55034-9.
PMID33725344.
S2CID232261340.